Furthermore, a multivariate model that included the most relevant factors that predict outcome in this group of patients, underlined the predictive role of SFN. Overall these results indicate that, even if PCDHB methylation can correctly subdivide stage 4 patients in distinct risk groups, it is not a prognostic indicator in stage 4 high-risk neuroblastoma patients. Here, SFN is linked to neuroblastoma.